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Abstract
Today, one of the most important global public health challenges is represented by hepatitis C virus (HCV), which
imposes relevant costs. Globally speaking, the median cost of HCV-related complications ranges from $280 for an
uncomplicated hepatitis to $139,070 for a liver transplantation. There are effective therapies for HCV patients worldwide,
which has increased the hope of improving the process of managing and curing these patients. The adherence of
patients to the pharmacological treatment and the use of effective drugs in the management of HCV disease are of
crucial importance for health policy- and decision-makers. Studies show that, globally, insurance coverage for patients
with HCV is not adequate in that still many patients are not covered by insurance programs. This issue as well as the
economic conditions of countries are very serious challenges for ensuring an effective treatment. The most
important and greatest help currently available to ensure HCV treatment is to implement plans to reduce costs
and support patients. Some studies have shown that the expansion of coverage by private payers seems able to
generate positive spillover benefits to public insures. Insurers, in addition to maintaining and increasing their own
interests, are trying to increase their social status as a sponsor of patients. In conclusion, HCV disease requires
serious policies and affordable insurance coverage.
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Main text
HCV epidemiology
Today, one of the most important global public health
challenges is represented by hepatitis C virus (HCV),
which imposes a dramatically relevant burden in terms of
morbidity and mortality in many parts of the world. As
such, the health sectors of the different countries have de-
signed and implemented various programs for preventing,
controlling and treating HCV [1]. According to the World
Health Organization (WHO), 399,000 people die annually
due to HCV and its complications, such as cirrhosis and
liver cancer. This represents a major source of concern for
health decision- and policy-makers [2].
There are effective therapies for HCV patients worldwide,
which has increased the hope of improving the process of
managing and curing these patients [3]. With the
emergence of new viral treatments such as direct-acting an-
tivirals (DAAs), the health sectors of the different countries
are working to provide treatment for these people in order
to increase their quality of life (QOL) and prevent compli-
cations related to the disease [4].
HCV-generated economic burden
HCV is responsible for a huge economic burden for the
countries of the world [5]. Direct costs (related to med-
ical expenses for hepatic and extra-hepatic complications
of HCV) as well as indirect costs (incurring from
impaired QOL, and the loss of work productivity due to
inability) have become a real challenge worldwide [6, 7].
In particular [8], according to a recent systematic review
and meta-analysis of 102 studies, extra-hepatic compli-
cations such as diabetes (occurring in 15% of patients)
and depression (occurring in approximately 25% of pa-
tients) are the major drivers of such relevant economic
burden. Due to financial constraints, the health systems
of many countries, in many cases, are not able to cover
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most of the costs generated by the treatment for these
patients [7]. Direct, indirect, cumulative and lifetime
costs generated by HCV vary according to the setting
and the health system adopted; estimates computed for
different countries are reported in Table 1 [9–19].
The role of insurance programs
Economic-financial crises, rising HCV infection incidence
rates, the availability of new biomedical technologies, and
increased staff costs are the main factors that have limited
the allocation of funding for the health sector and, as such,
healthcare decision- and policy-makers are not able to meet
with all the population’s health needs to properly satisfy
them [20].
As a result, many patients face serious problems in having
their disease properly managed and treated. This has pre-
vented the establishment of a universal financial protection
for these patients from the health sectors. In the meantime,
increased out-of- pocket (OOP) expenditure has made it
difficult for the poor people to meet their health-related
needs [21].
The adherence of patients to the pharmacological treat-
ment and the use of effective drugs in the management of
HCV disease are of crucial importance for health decision-
and policy-makers. Despite the effectiveness of DAAs [22],
drug prices are high, and many patients are not able to pay
for these costs. Therefore, many of them cannot use these
medications and the treatment process is facing serious
challenges [23].
The WHO reported in 2013 on trends in countries’
policies and programs related to hepatitis. In this re-
port, many countries have referred to drugs for the
treatment of HCV patients for activities such as drug
subsidies, but one of the things that should be con-
sidered by health decision- and policy-makers is the
lack of insurance coverage for these patients. In de-
veloped and developing countries, insurers do not
play, indeed, a major role in helping/assisting HCV
patients [24].
Studies show that, globally, insurance coverage for
patients with HCV is not adequate in that still many
patients are not covered by insurance programs. This
issue and the economic conditions of countries





Cumulative cost Lifetime cost
USA [9] $6.5 ($4.3–8.4) billion, increasing to $9.1




56–81% (due to cirrhosis and its complications) 19–44% $64,694
Germany
[11]
Mean total cost per patient for hepatic complications
€556–1425, for extra-hepatic complications €1921-3547,
for chronic HCV €116–577, for non-chronic HCV-related
pharmacy costs €1479–3719
Mean total cost per patient €5430-10,108
Belgium
[12]
€126 million (€30–257 million) €1850 million
France [13] 84% (47% due to liver cirrhosis, 18% to hepatocarcinoma
and 19% to liver transplantation)
16% €65,956,938
Spain [14] 71.5% 28.5% Mean total cost per patient €3198
UK [15] £97,555–125,359 for
disability, £26,424–
32,235 for healthcare
Ireland [16] Mean total cost per patient €38,286–
62,457 (interferon-based regimen),
€55,734–81,873 (interferon-free regimen)
Italy [17] 39.4% 60.6% €1.06 billion
Iran [18] Total annual cost per patient USD1625.50, USD6,117.2,




Median cost of liver transplantation $139,070 ($15,430-
443,700), refractory ascites $16,740 ($8990-35,940),
hepatocellular carcinoma $15,310 ($3370-84,710),
decompensated cirrhosis $14,660 ($3810-48,360), variceal
hemorrhage $12,190 ($3550-46,120), hepatic
encephalopathy $9180 ($5370-50,120), diuretic sensitive
ascites $3400 ($1320-7470), compensated cirrhosis $820
($50–2890), and chronic hepatitis C $280 ($90–1860).
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represent very serious challenges for ensuring an effect-
ive treatment [25, 26].
Insurers have a very important role to play in support-
ing the health sector in creating financial resources and
helping people to offset the financial catastrophe by
offering support. Insurance should improve the process
of treating HCV disease and play a more vibrant role in
facilitating this process [27], ensuring, for instance, the
continuity between HCV screening and healthcare (the
so-called HCV screening and linkage-to-care or SLTC
continuum or care cascade, which include different sub-
sequent steps, namely: diagnosis, linkage to care, reten-
tion in care, prescription of antiretroviral therapy, and
sustained virologic response/viral suppression) [28].
Medical expenses are causing poverty and financial ca-
tastrophe to patients and their families [29], and the pay-
out increases from the OOP. Unfortunately, in patients
with HCV, the increase in OOP has made the treatment
problematic [30]. On the other hand, those who have
been insured have been able to enjoy good antiviral
treatment and, in addition to recovery, this will reduce
the HCV-generated economic burden [31].
The need for a consolidation and integration of the
various insurance programs
There are diverse insurance providers, either public or
commercial, offering a variety of programs and plans, such
as government public programs for employees, or for
urban and rural areas/settings, and government-provided
catastrophic health insurance, or commercial health insur-
ance programs. As such, creating an alliance for insurance
managers is very important, to meet with different health
needs, specific populations and curb costs, while, at the
same time, delivering high-quality healthcare services.
Consolidation and integration of payers and providers,
leading to a “mosaic of insurance programs” can result in
greater value and clinical safety in a sustainable way. “In a
typical integrated network, the payers stipulate a frame-
work whereby provider groups agree to care for a specific
patient population with the goal of reaching or surpassing
a predetermined set of quality and cost benchmarks. The
integration model encourages healthcare organizations to
deliver value to patients and reduce the overuse of treat-
ments” [32].
Insurers should understand the conditions of the dis-
ease and the treatment of patients. Many insurance
companies are unwilling to participate in the treatment
of HCV patients due to their high costs. Meanwhile,
some healthcare decision- and policy-makers seem to
have overlooked the importance of treating these pa-
tients and are indifferent to them [33].
Due to the economic conditions of countries and the
crises that every day affect the health system, negotiating
with insurance managers is becoming more and more
fundamental. If we want to achieve the goal of eliminat-
ing/eradicating HCV by the year 2030 [34], in addition
to the Ministry of Health (MoH), other organizations,
such as insurance companies, should be the main
trustees that provide healthcare services to patients.
Treatment and adherence to patients are not complete
unless the cost of treatment for them is lower and af-
fordable and treatment provides these patients with bet-
ter conditions for control and prevention. Reducing this
disease, especially by increasing the use of injectable
drugs, can be very effective in improving the overall
health of the population [25].
Obstacles and barriers for insurers in ensuring treatment
access to HCV patients
There are different obstacles and barriers to ensure
treatment access for HCV patients. For instance, there is
a gap between health decision- and policy-makers and
insurance managers/providers, and this could be a ser-
ious warning for the treatment of HCV patients. This
gap can be due to different goals, aims, and perspectives
(public health and societal point of view versus commer-
cial purposes).
In order to cope with the high costs of the new DAA
regimens, some insurers are restricting access to medica-
tions, establishing selective criteria for reimbursement.
Gowda and collaborators [35] performed a prospective
cohort study among American HCV patients. Authors
found that absolute denials of DAA regimens by insurers
have remained high and increased over time.
It should be emphasized that the health department is
not a closed system and it has to use the high and effect-
ive potential of insurance programs. Insurers offering
support to target and beneficiary groups can play a very
valuable role in the treatment process. Health decision-
and policy-makers can provide their support for HCV
treatment by effectively communicating with insurers
[36].
Opportunities for insurers
The most important and greatest help currently available
to guarantee HCV treatment is to implement plans to
reduce costs and support patients. Of course, it should
not be forgotten that insurers have a benefit in addition
to their support for the health plan, which should also
be addressed by policy- and decision-makers. Govern-
ments can give them concessions to obtain insurance,
and provide insurance companies with incentives to sup-
port patients for further economic-financial coverage
[26]. In the USA, Medicaid reimbursement [37] for ther-
apeutics needed for the proper management and treat-
ment of HCV infection has increased from $723 million
to $2.35 billion in the period 2012–2015. Significant var-
iations in the Medicaid reimbursement scheme for
Behzadifar et al. BMC Health Services Research           (2019) 19:25 Page 3 of 6
DAAs between states in 2014 could be detected that be-
came even more evident in 2015. Expansion states were
characterized by a higher increase in reimbursement for
DAAs per individual suffering from HCV infection with
respect to non- or late-expansion states, adjusting for
pre-expansion reimbursement. In conclusion, approxi-
mately a third of states contributed more than 5–15% of
pharmacy reimbursements to DAAs. New healthcare
policies are, therefore, urgently needed in order to en-
sure coverage for an increasing number of expensive
drugs required for the effective treatment of a rising
number of patients.
Furthermore, according to a mathematical model ana-
lysis [38], the pricing scheme of drugs for the manage-
ment of HCV infection seems to follow a value-based
model, with a rather steady ratio of costs per achieved
sustained virologic response over a period of 25 years.
This leads to the paradoxical conundrum that healthcare
systems are challenged by the economic-financial issues
arising by the high resource utilization of these new
drugs despite their cost-effectiveness [39] and their
short- and long-term benefits in terms of health. There-
fore, a synergy among the different stakeholders
(pharmaceutical industries, healthcare payers and insur-
ance providers) should be sought and established in
order to find innovative drug pricing schemes to manage
all the HCV patients.
Treating all eligible Medicaid patients [40], regardless
of fibrotic stage, was computed to result in significantly
fewer liver transplants and cases of cirrhosis, hepatocel-
lular carcinoma and HCV-related deaths, as well as in
significantly additional life-years and quality-adjusted
life-years per patient. Treating all Medicaid chronic
HCV patients was projected to result in significant cost
savings and total costs of care reduction. However, the
“treat-all” strategy appears to be promising and
cost-effective, if properly supported by new funding and
payment schemes, such as cost-sharing mechanisms
[41], like plan premiums, deductibles, co-payments, and
coinsurance, among others [42].
The roles of the different insurance programs
The role of health insurance programs is recognized as a
major contribution to the health sector and should be
used to promote and improve health plans. Insurers can
ensure pharmacological treatment and management to
many poor people unable to receive health services, and
governments can diversify their healthcare service pack-
ages. Insurers, in addition to maintaining and increasing
their own interests, are trying to increase their social sta-
tus as a sponsor of patients.
However, discrepancies between public and private/
commercial insurance providers do exist. Such discrep-
ancies could be due to economic factors. For instance,
Mukka et al. [26], in a retrospective study of 160 HCV
patients, found that patients with private insurance were
more likely to receive treatment compared to patients
with public aid. Vu and colleagues [43] performed a
multivariate regression analysis and found that predic-
tors of fewer steps in the authorization cascade were
having non-Medicaid insurance, and being HCV non
genotype 2. At the survival analysis, non-Medicaid insur-
ance and mid-range fibrosis were significantly associated
with fewer days to the authorization approval.
On the other hand, the role of private/commercial
insurance providers can be positive. Moreno and collab-
orators [44] have modeled the costs and spillover effects
of private insurers’ coverage and have found that, with
expanded HCV treatment coverage, private payers may
reduce medical expenditures, and, over a 20-year period,
may experience even overall savings, also generating
positive spillover effects to insures like Medicare.
Conclusions
In conclusion, HCV disease is a challenging public
health issue, that requires serious policies and affordable
insurance coverage. Patients need to receive drugs, and
bad economic conditions can represent barriers to the
treatment, leading to poor access to healthcare. Negotia-
tions between health decision- and policy-makers and
insurance managers, either public or private, should be
taken seriously. Preventing a higher incidence of disease
should be a major concern for them. With the increasing
incidence of disease in recent years, support for ensuring
treatment of patients is very important and everyone
should feel the onus to try to reduce the disease. Finan-
cial support for patients with HCV is very important
and patients should not be liable for their costs. Insur-
ance is an effective leverage for the adherence of all
patients to treatment.
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